Datapoint: Supreme Court Cements Vascepa Patent Loss

The United States Supreme Court on Monday declined to hear Amarin’s arguments against patent loss for its fish oil derivative drug Vascepa. A federal appeals court in September upheld a lower court ruling that definitively invalidates the patent, meaning generic challengers, including one from Hikma Pharmaceuticals, can move forward. Amarin had blockbuster hopes for the heart drug, which the FDA approved in December 2019. Vascepa currently holds preferred status for 33% of all covered lives under the pharmacy benefit, growing to 52% with utilization management restrictions. The drug holds covered or better status for 94% of all insured lives.

SOURCE: MMIT Analytics, as of 6/23/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 8

Datapoint: Aetna-Allina Health Launch New Plan Designs in Minnesota

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 7

Datapoint: Oklahoma Medicaid Rolls Top 1M After Expansion

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 6

Datapoint: Blue Cross and Blue Shield of Montana Plots Medicare Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today